<DOC>
	<DOCNO>NCT01386580</DOCNO>
	<brief_summary>The purpose study determine safety , tolerability , pharmacokinetics ( PK ) 2B3-101 single agent combination trastuzumab . Furthermore , study explore preliminary antitumor activity 2B3-101 single agent patient solid tumor brain metastasis recurrent malignant glioma well patient various form breast cancer combination trastuzumab HER2+ breast cancer patient brain metastasis .</brief_summary>
	<brief_title>An Open-label , Phase I/IIa , Dose Escalating Study 2B3-101 Patients With Solid Tumors Brain Metastases Recurrent Malignant Glioma .</brief_title>
	<detailed_description>This Phase I/IIa , multicenter , open-label , dose-escalation study . The study conduct 6 phase : `` 2B3-101 single agent dose-escalation phase '' , `` 2B3-101 trastuzumab dose-escalation phase '' , `` Breast cancer brain metastases study-expansion phase '' , '' Recurrent malignant glioma study-expansion phase '' , `` Melanoma brain metastases study- expansion phase '' `` SCLC brain metastasis study-expansion phase '' 2B3-101 single agent dose-escalation phase . In 2B3-101 single Agent dose-escalation phase , female male patient solid tumor brain metastasis recurrent malignant glioma enrol . Patients assign dose level cohort . - The start dose 5 mg/m2 , equal 1/10 human equivalent dose LD10 2B3-101 rat . A `` 3+3 '' dose-escalation design use . The study investigate sequential cohort consist 3-6 patient enrol treated applicable dose level . Planned dose level subsequent cohort 10 , 20 , 30 , mg/m2 step 10 mg/m2 thereafter . For information dose escalation design increment , please see dose escalation criterion section . There intra-patient dose escalation . Each treatment cycle consist 21 day . Patients receive single IV dose 2B3-101 day 1 cycle . In order minimize risk infusion reaction 5 % total dose 2B3-101 ( mg ) infuse slowly first 30 minute . If tolerate , infusion may complete next hour total infusion time 90 minute . Blood sample take day 1 , 2 , 3 , 5 , 8 11 cycle 1 day 1 , 8 15 cycle 2 ass PK profile first 2 cycle . The dose limiting toxicity ( DLT ) observation period dose level cycle 1 ( day 1 day 21 ) . Patients complete DLT observation period ( cycle 1 ) reason DLT replace . Once MTD 2B3-101 single agent determine , study continue breast cancer brain metastasis recurrent malignant glioma dose expansion phase . 2B3-101 combination trastuzumab dose-escalation phase In 2B3-101 combination trastuzumab dose escalation phase , patient HER2+ breast cancer brain metastasis enrol . The patient assign 2B3-101 dose level cohort . - The start dose 2B3-101 40 mg/m2 every 3 week . This dose select base upon safety information patient treat 2B3-101 dose level , well upon previous treatment PEGylated liposomal doxorubicin combination trastuzumab ( Chia et al 2006 ) . The dose-escalation conduct step 10 mg/m2 MTD level determine 2B3-101 single agent . The trastuzumab dose remain fixed load dose 8 mg/kg day 1 6 mg/kg every 3 week subsequent cycle throughout determination MTD . Enrolment HER2+ patient breast cancer patient `` 2B3-101 combination trastuzumab dose-escalation '' phase study allow parallel determination MTD 2B3-101 single agent . A `` 3+3 '' dose-escalation design use . Thus , study investigate sequential cohort 3-6 patient , enrol treat applicable dose level . No intra-patient dose-escalation allow . Each treatment cycle consist 21 day . All patient receive single IV dose 2B3-101 day 1 cycle . In order minimize risk infusion reaction 5 % total dose 2B3-101 ( mg ) infuse slowly first 30 minute . As long 2B3-101 well tolerate , remain 95 % infusion could thereafter administer next 60 min , result total infusion time 90 minute . The infusion trastuzumab follow 30 minute completion 2B3-101 infusion . Blood sample take day 1 , 2 , 3 , 5 , 8 11 cycle 1 , day 1 , 8 15 cycle 2 applicable day 1 cycle 3 day 1 cycle 4 ass PK profile 2B3-101 first 4 cycle . The dose limiting toxicity ( DLT ) observation period cycle 1 ( day 1 day 21 ) individual dose level . Patients complete DLT observation period ( cycle 1 ) reason DLT replace . Breast cancer brain metastasis expansion phase . In breast cancer brain metastasis expansion phase , treatment cycle consist 21 day . Patients receive single IV dose 2B3-101 day 1 cycle . In order minimize risk infusion reaction 5 % total dose 2B3-101 ( mg ) infuse slowly first 30 minute . If tolerate , infusion may complete next hour total infusion time 90 minute . Blood sample take day 1 , 2 , 3 , 5 , 8 11 cycle 1 day 1 , 8 15 cycle 2 applicable day 1 cycle 3 day 1 cycle 4 ass PK profile first 4 cycle . Recurrent malignant glioma expansion phase . In recurrent malignant glioma expansion phase , treatment cycle 28 day long . Patients receive single IV dose 2B3-101 day 1 cycle . In order minimize risk infusion reaction 5 % total dose 2B3-101 ( mg ) infuse slowly first 30 minute . If tolerate , infusion may complete next hour total infusion time 90 minute . Blood sample take day 1 , 2 , 3 , 5 , 8 11 cycle 1 , day 1 , 8 15 cycle 2 applicable day 1 cycle 3 day 1 cycle 4 ass PK profile first 4 cycle . SCLC brain metastasis study arm expansion phase In SCLC brain metastasis study arm expansion phase , treatment cycle 21 day long . Patients receive single IV dose 2B3-101 MTD determine 2B3-101 single agent day 1 cycle . In order minimize risk infusion reaction 5 % total dose ( mg ) infuse slowly first 30 minute . As long 2B3-101 well tolerate , remain 95 % infusion could thereafter administer next 60 minute , result total infusion time 90 minute . Blood sample take day 1 , 2 , 3 , 5 , 8 11 cycle 1 , day 1 , 8 15 cycle 2 applicable day 1 cycle 3 day 1 cycle 4 ass PK profile first 4 cycle . Melanoma brain metastasis study arm expansion phase In melanoma brain metastasis study arm expansion phase , treatment cycle 21 day long . Patients receive single IV dose 2B3-101 MTD determine 2B3-101 single agent dose escalation phase day 1 cycle . In order minimize risk infusion reaction 5 % total dose ( mg ) infuse slowly first 30 minute . As long 2B3-101 well tolerate , remain 95 % infusion could thereafter administer next 60 minute , result total infusion time 90 minute . Blood sample take day 1 , 2 , 3 , 5 , 8 11 cycle 1 , day 1 , 8 15 cycle 2 applicable day 1 cycle 3 day 1 cycle 4 ass PK profile first 4 cycle . For stages patient stay treatment disease progression , unacceptable toxicity , discontinuation reason .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>1 . Age ≥ 18 year . 2 . Measurable intracranial disease MRI . 3 . ECOG Performance Status ≤ 2 . 4 . Estimated life expectancy least 8 week . 5 . Toxicities incur result previous anticancer therapy ( radiation therapy , chemotherapy , surgery ) must resolve ≤ grade 2 ( define CTCAE version 4.0 ) . 6 . No evidence ( cortical ) cognitive impairment define MiniMental Status Exam ( MMSE ) score ≥ 25/30 . 7 . Written inform consent accord local guideline . In addition list eligibility criterion , follow criterion applicable : 8 . 2B3101 single agent doseescalation phase : 1 . Patients pathologically confirm diagnosis advance , recurrent solid tumor unequivocal evidence brain metastasis refractory standard therapy standard therapy exist unequivocal evidence newly diagnose untreated brain metastasis control extracranial disease per multidisciplinary team decision require immediate radiotherapy , surgery standard systematic chemotherapy . Brain metastasis may stable , progressive , symptomatic asymptomatic brain metastasis/es . Stable decrease dosage steroid ( e.g . dexamethasone ) 7 day prior baseline MRI nonenzyme induce antiepileptic drug allow . Or 2 . Patients pathology confirm diagnosis advance , recurrent primary malignant ( grade III IV ) glioma refractory standard therapy standard therapy exist . Stable decrease dosage steroid ( e.g . dexamethasone ) 7 day prior baseline MRI nonenzyme induce antiepileptic drug allow . 2B3101 combination trastuzumab dose escalation phase : Patients histologicallyconfirmed HER2positive ( IHC 3+ fluorescence situ hybridization [ FISH ] amplify ; clinical assay either primary metastatic tumor ) adenocarcinoma breast unequivocal evidence brain metastasis refractory standard therapy standard therapy exist unequivocal evidence newly diagnose untreated brain metastasis control extracranial disease per multidisciplinary team decision require immediate radiotherapy , surgery standard systematic chemotherapy include escalation phase well . Breast cancer brain metastasis expansion phase : 1 . Patients pathologically confirm diagnosis advance , recurrent breast cancer least one progressive and/or new metastatic brain lesion , refractory standard therapy standard therapy exist . Brain metastasis may stable , progressive , symptomatic asymptomatic brain metastasis/es . Stable decrease dosage steroid ( e.g . dexamethasone ) 7 day prior baseline MRI nonenzyme induce antiepileptic drug allow . Or 2 . Patients pathologically confirm diagnosis advance breast cancer newly diagnose , untreated , brain metastasis control extracranial disease per multidisciplinary team decision require immediate radiotherapy , surgery standard systematic chemotherapy . SCLC brain metastasis study arm expansion phase : 1 . Patients pathologically confirm diagnosis advance , recurrent SCLC least one progressive and/or new metastatic brain lesion refractory standard therapy standard therapy exist . Stable decrease dosage steroid ( e.g . dexamethasone ) 7 day prior baseline MRI and/or use nonenzyme induce antiepileptic drug allow . Or 2 . Patients pathologically confirm diagnosis advance SCLC newly diagnose , untreated , brain metastasis control extracranial disease per multidisciplinary team decision require immediate radiotherapy , surgery standard systematic chemotherapy . Melanoma brain metastasis study arm expansion phase : 1 . Patients pathologically confirm diagnosis advance , recurrent melanoma least one progressive and/or new metastatic brain lesion refractory standard therapy standard therapy exist . Stable decrease dosage steroid ( e.g . dexamethasone ) 7 day prior baseline MRI and/or use nonenzyme induce antiepileptic drug allow . Or 2 . Patients pathologically confirm diagnosis advance melanoma newly diagnose , untreated , brain metastasis control extracranial disease per multidisciplinary team decision require immediate radiotherapy , surgery standard systematic chemotherapy . Recurrent malignant glioma study arm expansion phase : 1 . 7 patient histologically proven glioma grade IV , progressive follow first line treatment surgery biopsy follow fractionated radiotherapy concurrent temozolomidecontaining chemotherapy . 2 . 7 patient recurrent histologically confirm malignant ( WHO grade III IV ) glioma histologically confirm lowgrade ( WHO grade II ) glioma radiographic evidence malignant transformation MRI , refractory standard therapy , standard therapy exist require immediate standard therapy per multidisciplinary team decision . Patients group stable decrease dosage steroid ( e.g . dexamethasone ) minimum 7 day prior baseline MRI . Nonenzyme induce antiepileptic drug allow Exclusion Criteria . Prior Treatment . 1 . Less 1 week since last treatment lapatinib , less 2 week since last treatment vemurafenib , less 4 week since last treatment chemotherapy , biological therapy , immunotherapy systemic radiotherapy ( except palliative radiation deliver &lt; 20 % bone marrow ) , less 8 week cranial radiotherapy , less 6 week nitrosoureas mitomycin C. 2 . Patients receive maximum cumulative dose free ( i.e. , nonliposomal ) liposomal doxorubicin &gt; 360mg/m2 free epirubicin &gt; 600mg/m2 . Current Treatment . 3 . Current recent ( within 30 day first study treatment ) treatment another investigational drug participation another investigational study . Hematology , coagulation biochemistry . 4 . Inadequate bone marrow function : Absolute Neutrophil Count ( ANC ) : &lt; 1.5 x 109/L , platelet count &lt; 100 x 109/L hemoglobin &lt; 6 mmol/L . 5 . Inadequate liver function , define : • Serum ( total ) bilirubin &gt; 1.5 x ULN institution liver metastasis ( &gt; 2 x ULN patient liver metastasis ) ; • ASAT ALAT &gt; 2.5 x ULN liver metastasis ( &gt; 4 x ULN patient liver metastasis ) ; Alkaline phosphatase level &gt; 2.5 x ULN liver metastasis ( &gt; 5 x ULN patient liver metastasis , &gt; 10 x ULN patient bone metastasis ) . 6 . Inadequate renal function , define : Serum creatinine &gt; 1.5 x ULN . Other . 7 . Leptomeningeal carcinomatosis site CNS involvement . 8 . Pregnancy lactation . Serum pregnancy test perform within 7 day prior study treatment start , within 14 day follow confirmatory urine pregnancy test within 7 day prior study treatment start . 9 . For female subject childbearing potential ( define &lt; 2 year last menstruation surgically sterile ) male subject surgically sterile female partner childbearing potential : absence effective , nonhormonal mean contraception ( intrauterine contraceptive device , barrier method contraception conjunction spermicidal gel ) . 10 . Major surgical procedure ( include open biopsy , exclude central line IV portacath ) within 28 day prior first study treatment , anticipation need major surgery course study treatment . 11 . Grade 3 4 motor , sensory , cranial neuropathy symptom ( define CTCAE version 4.0 ) . 12 . Uncontrolled hypertension ( systolic &gt; 150 mm Hg and/or diastolic &gt; 100mm Hg ) . 13 . Clinically significant ( i.e . active ) cardiovascular disease define : • Stroke within ≤ 6 month prior day 1 ; • Transient Ischemic Attack ( TIA ) within ≤ 6 month prior day 1 ; • Myocardial infarction within ≤ 6 month prior day 1 ; • Unstable angina ; New York Heart Association ( NYHA ) Grade II great Congestive Heart Failure ( CHF ) ; Serious cardiac arrhythmia require medication ; Clinically relevant pathologic finding ECG . 14 . Left Ventricle Ejection Fraction ( LVEF ) MUGA ECHO &lt; 55 % patient receive 2B3101 combination trastuzumab . For patient receive single agent 2B3101 treatment . Left Ventricle Ejection Fraction ( LVEF ) MUGA ECHO &lt; 50 % . 15 . Known hypersensitivity study drug excipients ( e.g . doxorubicin , PEG GSH ) . 16 . Evidence medical condition ( psychiatric illness , infectious disease , physical examination laboratory finding ) may interfere plan treatment , affect patient compliance place patient high risk treatmentrelated complication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Brain Neoplasms</keyword>
	<keyword>Neoplasm Metastasis</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Central Nervous System Neoplasms</keyword>
	<keyword>Nervous System Neoplasms</keyword>
	<keyword>Neoplasms Site</keyword>
	<keyword>Brain Diseases</keyword>
	<keyword>Central Nervous System Diseases</keyword>
	<keyword>Nervous System Diseases</keyword>
	<keyword>Neoplastic Processes</keyword>
	<keyword>Pathologic Processes</keyword>
</DOC>